3 recruiting, 3 terminated, 2 completed, 1 active not recruiting. 5 Phase 1, 2 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 3, Terminated 2 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Early Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Metastatic Endometrial Cancer: new trials by email Literature Review of Metastatic Endometrial Cancer trials Research Report on Metastatic Endometrial Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer anti-PD1 agent therapy - 1 year, anti-PD1 agent therapy - 2 years - Endometrial Adenocarcinoma, Metastatic Endometrial Cancer | Phase 3 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 140 | 2026-10-01 | 2026-10-15 |
| Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. ARR-002 - Ovarian Cancer, Endometrial Cancer | Phase 1 | Recruiting | ArriVent BioPharma, Inc. | 180 | 2026-07-23 | 2026-09-03 |
| A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors ERX-315 - Advanced Solid Tumor, Metastatic Breast Cancer | Phase 1 | Recruiting | EtiraRx Australia Pty Ltd | 36 | 2024-10-14 | 2026-05-29 |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NKT3964, Paclitaxel, Doxorubicin - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | NiKang Therapeutics, Inc. | 238 | 2024-09-19 | 2026-10-30 |
| Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study Metastatic Endometrial Cancer | Completed | ARCAGY/ GINECO GROUP | 351 | 2024-08-19 | 2025-03-20 | |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer Biopsy, Carboplatin, Paclitaxel - Lynch Syndrome, Recurrent Endometrial Carcinoma | Early Phase 1 | Terminated | Floor Backes, MD | 2 | 2021-07-01 | 2025-02-13 |
| Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer Rucaparib, Placebo Oral Tablet - Metastatic Endometrial Cancer | Phase 2 | Completed | University of Colorado, Denver | 79 | 2019-03-06 | 2026-03-24 |
| Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Durvalumab, Tremelimumab, Radiation Therapy - Recurrent Gynecological Cancer, Metastatic Cervical Cancer | Phase 1 | Terminated | Dana-Farber Cancer Institute | 16 | 2018-06-01 | 2025-05-31 |
| Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer Avelumab, Talazoparib, Axitinib - Metastatic Endometrial Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 106 | 2016-11-14 | 2026-07-28 |
Endometrial Neoplasms (10) · Ovarian Neoplasms (5) · Neoplasm Metastasis (3) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Uterine Diseases (2) · Breast Neoplasms (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · Liver Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Turcot syndrome (1) · Uterine Cervical Neoplasms (1) · Vaginal Neoplasms (1)
Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Genital Diseases (10) · Genital Diseases, Female (10) · Genital Neoplasms, Female (10) · Neoplasms by Site (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10) · Uterine Neoplasms (10) · Neoplasms (9) · Uterine Diseases (8) · Adnexal Diseases (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Gonadal Disorders (5)
Paclitaxel (2) · Axitinib (1) · Biopsy (1) · Carboplatin (1) · Doxorubicin (1) · Radiotherapy (1) · Taxes (1) · avelumab (1) · durvalumab (1) · rucaparib (1) · talazoparib (1) · tislelizumab (1) · tremelimumab (1)
Dana-Farber Cancer Institute (2) · NiKang Therapeutics, Inc. (2) · ARCAGY/ GINECO GROUP (1) · ArriVent BioPharma, Inc. (1) · EtiraRx Australia Pty Ltd (1) · Floor Backes, MD (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Colorado, Denver (1)
United States (8) · Australia (1) · France (1) · South Korea (1)
Bradley Corr, MD (1) · Floor Backes, MD (1) · Martin King, MD, PhD (1) · Olivia D Lara, MD, MS (1) · Panagiotis Konstantinopoulos, MD, PhD (1) · Rasha Cosman, MBBS (1)
PMID 35900726, PMID 40273550, PMID 40700852
P30CA046934 (1)